Safety of a Medicinal Product Based on Human Glial Progenitor Cells: A Pilot Study of Retrobulbar Administration in C57BL/6J Mice

INTRODUCTION. Stem cell therapy is a promising treatment method for various diseases and injuries, but its safety has yet to be determined. Therefore, studying the safety of administering a xenogeneic cell-based medicinal product (CBMP) into the retro-orbital venous sinus is essential for developing protocols for further studies of potential medicinal products for neurological conditions.

AIM. The aim of the study was to determine the optimal dose of a CBMP derived from glial progenitor cells (GPCs) and to evaluate its safety during retrobulbar administration in C57BL/6J mice.

MATERIALS AND METHODS. GPCs were derived from human induced pluripotent stem cells by stepwise differentiation and cultured in DMEM/F12 supplemented with epidermal growth factor and ciliary neurotrophic factor. Matrigel was used as a substrate. GPCs were injected into the retro-orbital venous sinus of male C57BL/6J mice under isoflurane anaesthesia once a week for two months. The study analysed changes in biochemical blood parameters and behaviour. The quantities of activated astrocytes and glial cells were determined by postmortem immunohistochemical staining.

RESULTS. The administration of GPCs at a dose of 500×10³ cells/mouse, which was selected using literature data, induced an increase in the plasma levels of ala nine aminotransferase and aspartate aminotransferase. This could indicate cell damage and the development of inflammatory reactions. At doses reduced to one-third the initial GPC concentration or lower, the biochemical blood parameters of the treatment groups did not differ significantly from those of the control group. There were no significant differences in neuroinflammatory markers between the groups receiving GPCs at different doses, except for an increase in astrocyte activation at a dose of 150×10³ cells/mouse, which could potentially indicate inflammatory processes in the brain. The study detected no pathological changes in the brain or cell damage markers in the blood of mice after retrobulbar GPC injections of 15×10³ or 50×10³ cells/mouse.

CONCLUSIONS. The study results indicate that long-term therapy with GPCs is potentially safe for mice if the dose is optimal. The authors suggest using the optimal doses and the administration route established in this study for further research into the safety of intravenous administration of CBMPs for neurological conditions.

1. Cecerska-Heryć E, Pękała M, Serwin N, Glizniewicz M, Grygorcewicz B, Michalczyk A, et al. The use of stem cells as a potential treatment method for selected neurodegenerative diseases: review. Cell Mol Neurobiol. 2023;43(6):2643–73. https://doi.org/10.1007/s10571-023-01344-6

2. Cherkashova EA, Burunova VV, Bukharova TB, Namestnikova DD, Gubskii IL, Salikhova DI, et al. Comparative analysis of the effects of intravenous administration of placental mesenchymal stromal cells and neural progenitor cells derived from induced pluripotent cells on the course of acute ischemic stroke in rats. Bull Exp Biol Med. 2019;166(4):558–66. https://doi.org/10.1007/s10517-019-04392-5

3. Namestnikova DD, Gubskiy IL, Salikhova DI, Leonov GE, Sukhinich KK, Melnikov PA, et al. Therapeutic efficacy of intra-arterial administration of induced pluripotent stem cells-derived neural progenitor cells in acute experimental ischemic stroke in rats. Russian Journal of Transplantology and Artificial Organs. 2019;21(1):153–64 (In Russ.). https://doi.org/10.15825/1995-1191-2019-1-153-164

4. Kalladka D, Sinden J, Pollock K, Haig C, McLean J, Smith W, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016;388(10046):787–96. https://doi.org/10.1016/s0140-6736(16)30513-x

5. Garitaonandia I, Gonzalez R, Christiansen-Weber T, Abramihina T, Poustovoitov M, Noskov A, et al. Neural stem cell tumorigenicity and biodistribution assessment for phase I clinical trial in Parkinson’s disease. Sci Rep. 2016;6:34478. https://doi.org/10.1038/srep34478

6. Neves AF, Camargo C, Premer C, Hare JM, Baumel BS, Pinto M. Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer’s disease. Exp Neurol. 2021;341:113706. https://doi.org/10.1016/j.expneurol.2021.113706

7. Wang Z, Peng W, Zhang C, Sheng C, Huang W, Wang Y, Fan R. Effects of stem cell transplantation on cognitive decline in animal models of Alzheimer’s disease: A systematic review and meta-analysis. Sci Rep. 2015;5:12134. https://doi.org/10.1038/srep12134

8. Zhang Y, Ren Z, Zou C, Wang S, Luo B, Li F, et al. Insulin-producing cells from human pancreatic islet-derived progenitor cells following transplantation in mice. Cell Biol Int. 2011;35(5):483–90. https://doi.org/10.1042/cbi20100152

9. Yasuhara T, Matsukawa N, Hara K, Yu G, Xu L, Maki M, et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson’s disease. J Neurosci. 2006;26(48):12497–511. https://doi.org/10.1523/jneurosci.3719-06.2006

10. Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB, et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis. 2004;16(1):68–77. https://doi.org/10.1016/j.nbd.2004.01.016

11. Lee H, Yun S, Kim IS, Lee IS, Shin JE, Park SC, et al. Human fetal brain-derived neural stem/progenitor cells grafted into the adult epileptic brain restrain seizures in rat models of temporal lobe epilepsy. PLoS One. 2014;9(8):e104092. https://doi.org/10.1371/journal.pone.0104092

12. Karvelas N, Bennett S, Politis G, Kouris N-I, Kole C. Advances in stem cell therapy in Alzheimer’s disease: a comprehensive clinical trial review. Stem Cell Investig. 2022;9:2. https://doi.org/10.21037/sci-2021-063

13. Tiwari S, Khan S, Kumar SV, Rajak R, Sultana A, Abjal Pasha S, et al. Efficacy and safety of neural stem cell therapy for spinal cord injury: a systematic literature review. Therapie. 2021;76(3):201–10. https://doi.org/10.1016/j.therap.2020.06.011

14. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545. https://doi.org/10.1186/s13287-021-02609-x

15. Wuputra K, Ku C-C, Wu D-C, Lin Y-C, Saito S, Yokoyama KK. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res. 2020;39(1):100. https://doi.org/10.1186/s13046-020-01584-0

16. Chapelin F, Khurana A, Moneeb M, Gray Hazard FK, Ray Chan CF, Nejadnik H, et al. Tumor formation of adult stem cell transplants in rodent arthritic joints. Mol Imaging Biol. 2019;21(1):95–104. https://doi.org/10.1007/s11307-018-1218-7

17. Zhou Q, Li T, Wang K, Zhang Q, Geng Z, Deng S, et al. Current status of xenotransplantation research and the strategies for preventing xenograft rejection. Front Immunol. 2022;13:928173. https://doi.org/10.3389/fimmu.2022.928173

18. Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringden O, Volk H-D, et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. 2019;25(2):149–63. https://doi.org/10.1016/j.molmed.2018.12.006

19. Boltze J, Jolkkonen J. Safety evaluation of intra-arterial cell delivery in stroke patients — a framework for future trials. Ann Transl Med. 2019;7(Suppl 8):S271. https://doi.org/10.21037/atm.2019.12.07

20. Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S. Retro-orbital injections in mice. Lab Anim (NY). 2011;40(5):155–60. https://doi.org/10.1038%2Flaban0511-155

21. Belousova EV, Salikhova DI, Nebogatikov VO, Ustyugov AA, Goldshtein DV. Stem cell-based therapy for Alzheimer’s disease. Laboratory Animals for Science. 2024;(1):52–60 (In Russ.). https://doi.org/10.57034/2618723X-2024-01-06

22. Salikhova D, Bukharova T, Cherkashova E, Namestnikova D, Leonov G, Nikitina M, et al. Therapeutic effects of hiPSC-derived glial and neuronal progenitor cells-conditioned medium in experimental ischemic stroke in rats. Int J Mol Sci. 2021;22(9):4694. https://doi.org/10.3390/ijms22094694

23. Wei X, Yang X, Han Z, Qu F, Shao L, Shi Y. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747–54. https://doi.org/10.1038/aps.2013.50

24. Jovic D, Yu Y, Wang D, Wang K, Li H, Xu F, et al. A brief overview of global trends in MSC-based cell therapy. Stem Cell Rev Rep. 2022;18(5):1525–45. https://doi.org/10.1007/s12015-022-10369-1

25. Podestà MA, Remuzzi G, Casiraghi F. Mesenchymal stromal cells for transplant tolerance. Front Immunol. 2019;10:1287. https://doi.org/10.3389/fimmu.2019.01287

26. Chin S-P, Saffery NS, Then K-Y, Cheong S-K. Preclinical assessments of safety and tumorigenicity of very high doses of allogeneic human umbilical cord mesenchymal stem cells. In Vitro Cell Dev Biol Anim. 2024;60(3):307–19. https://doi.org/10.1007/s11626-024-00852-z

27. Xu J, Liu G, Wang X, Hu Y, Luo H, Ye L, et al. hUC-MSCs: evaluation of acute and long-term routine toxicity testing in mice and rats. Cytotechnology. 2022;74(1):17–29. https://doi.org/10.1007/s10616-021-00502-2

28. Kyung J, Kim D, Shin K, Park D, Hong S-C, Kim TM, et al. Repeated intravenous administration of human neural stem cells producing choline acetyltransferase exerts anti-aging effects in male F344 rats. Cells. 2023;12(23):2711. https://doi.org/10.3390/cells12232711

29. Lv Z, Li Y, Wang Y, Cong F, Li X, Cui W, et al. Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a randomized phase 1/2 controlled trial. Stem Cell Res Ther. 2023;14(1):23. https://doi.org/10.1186/s13287-022-03234-y

30. Rogujski P, Lukomska B, Janowski M, Stanaszek L. Glial-restricted progenitor cells: a cure for diseased brain? Biol Res. 2024;57(1):8. https://doi.org/10.1186/s40659-024-00486-1